Monday, 29 September 2014

A New Standard of Care in HER2 Breast Cancer

MADRID (MedPage Today) -- Adding two anti-HER2 agents to chemotherapy for metastatic disease increases media survival to almost 5 years. via MedPageToday.com - medical news plus CME for physicians Read More Here..
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)